Nevro Corp

Nevro — Q3 2024 Earnings Presentation

15 slides from Nevro's earnings presentation, Nov 14, 2024

  1. Slide 1: Third Quarter 2024 Earnings Conference Call

    ©2024 Nevro Corp. All rights reserved. S000000 Third Quarter 2024 Earnings Conference Call November 11, 2024 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    ©2024 Nevro Corp. All rights reserved. S000000 In addition to historical information, this presentation contains forward-looking statements reflecting the current beliefs and expectations of the company’s management, made pursuant to the safe harbor provisions of the Private Securities Litigation Re

  3. Slide 3: Non-GAAP Financial Measures

    ©2024 Nevro Corp. All rights reserved. S000000 Management uses certain non-GAAP financial measures, most specifically Adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the company’s operating performance period over period, analyze the underlying business trends, assess

  4. Slide 4: Business Overview and Financial Overview

    Business Overview Kevin Thornal Chief Executive Officer & President Financial Overview Rod MacLeod Chief Financial Officer & Senior Vice President

  5. Slide 5: Third-Quarter 2024 Financial Highlights

    ©2024 Nevro Corp. All rights reserved. S000000 Third-Quarter 2024 Financial Highlights ($ in Millions, except %) Q3 2024 Q3 2023 Change* Worldwide Revenue $96.9 $103.9 - 6.7% (as reported) - 7.0% (constant currency) U.S. Revenue $83.9 $89.8 -6.5% International Revenue $13.0 $14.1 -7.7% (as reported)

  6. Slide 6: Third quarter highlights and actions to return to growth

    ©2024 Nevro Corp. All rights reserved. S000000 ” Implementing actions to improve competitive positioning, drive market penetration, return to sustainable top-line growth and continue on path toward profitability Improving commercial execution by expanding territories led by newly promoted associate

  7. Slide 7: Implementing Actions to Improve Commercial Execution

    Implementing Actions to Improve Commercial Execution Promoted several new associate sales representatives (ASR) to lead newly created territories in 3Q24 with plan to add new territories in 2025 Expect ramp-up period in 2025 as new ASRs get established in their territories Allows sales team to reach

  8. Slide 8: Building and Leveraging R&D Pipeline to Drive Market Penetration

    Building and Leveraging R&D Pipeline to Drive Market Penetration HFX AdaptivAI received U.S. Food & Drug Administration (FDA) approval and announced limited market release (LMR) in September 2024 The only SCS technology using artificial intelligence (AI) and built on foundation of landmark evidence,

  9. Slide 9: Expanding SCS Therapy and Alternative Therapies Earlier in the Care Continuum

    Strategy to grow through expanded SCS therapy and alternative therapies earlier in the care continuum Continue to focus on growing painful diabetic neuropathy (PDN) business by educating physicians and raising patient awareness on benefits of SCS therapy New data published in Journal of Pain Medicin

  10. Slide 10: Full-Year 2024 Guidance

    Full-Year 2024 Guidance (As of November 11, 2024) Full-Year 2024 Guidance Worldwide Revenue(1) $400 million to $405 million Gross Margin ~ 66% (Adjusted gross margin of ~ 68% excluding one-time supplier contract renegotiation charge) Operating Expenses(2) ~$369.1 million (Previous guidance: ~ $383 m

  11. Slide 11: Becoming the Leading Comprehensive Pain Management Company

    Our goal is to become the leading comprehensive pain management company with a diversified, differentiated and innovative product portfolio SCS Indication Expansion Continue to Scale Costa Rica Manufacturing and Leverage Business Evaluate Strategic Opportunities Commercial Execution Penetrate SI Joi

  12. Slide 12: Appendix

    Appendix 12

  13. Slide 13: GAAP to Non-GAAP Adjusted EBITDA Reconciliation

    GAAP to Non-GAAP Adjusted EBITDA Reconciliation (Unaudited; dollars in thousands) The table below presents a reconciliation of GAAP net loss, as prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"), to adjusted EBITDA, a non-GAAP financial measure. Please refer to slide

  14. Slide 14: GAAP to Non-GAAP Adjusted EBITDA Reconciliation: FY24 Guidance

    GAAP to Non-GAAP Adjusted EBITDA Reconciliation (Unaudited; dollars in thousands) Note: Nevro has not provided a quantitative reconciliation of forecasted adjusted EBITDA to forecasted Net Loss because the company is unable, without making unreasonable efforts, to calculate certain reconciling items

  15. Slide 15: For more information about Nevro, contact

    angeline.mccabe@nevro.com For more information about Nevro, contact: Angie McCabe VICE PRESIDENT, INVESTOR RELATIONS & CORPORATE COMMUNICATIONS Nevro Corp. (NYSE: NVRO) 15

Nevro — Q3 2024 Earnings Presentation on 6ix